tiprankstipranks
CordovaCann Corp. (TSE:CDVA)
:CDVA
Want to see TSE:CDVA full AI Analyst Report?

CordovaCann (CDVA) AI Stock Analysis

0 Followers

Top Page

TSE:CDVA

CordovaCann

(CDVA)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 5.2)
Rating:50Neutral
Price Target:
C$0.04
▲(100.00% Upside)
Action:Reiterated
Date:05/31/26
The score is held back primarily by weak financial performance and a stressed balance sheet (negative equity and ongoing losses), despite improving operating momentum and recently positive operating/free cash flow. Technicals are supportive with price above key moving averages and positive MACD, but valuation remains constrained by negative earnings and no dividend data.
Positive Factors
Operating recovery (EBIT turned positive)
EBIT moving to positive on a TTM basis indicates the company has started to convert revenue into operating profits, reflecting sustainable cost control or mix improvement. That structural operating improvement reduces burn, supports internal funding, and lessens reliance on external capital over months.
Negative Factors
Negative shareholders' equity
Persistent negative equity signals cumulative losses and an impaired capital base, constraining financial flexibility. Over months this elevates refinancing and dilution risk, complicates raising debt or equity on favorable terms, and can limit strategic options if not remedied by sustained profits or capital injections.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating recovery (EBIT turned positive)
EBIT moving to positive on a TTM basis indicates the company has started to convert revenue into operating profits, reflecting sustainable cost control or mix improvement. That structural operating improvement reduces burn, supports internal funding, and lessens reliance on external capital over months.
Read all positive factors

CordovaCann (CDVA) vs. iShares MSCI Canada ETF (EWC)

CordovaCann Business Overview & Revenue Model

Company Description
CordovaCann Corp. is a company that focuses on various aspects of the cannabis industry, including identifying prospects, securing financing, developing new ventures, and managing operations throughout the entire cannabis value chain. As of Februa...

CordovaCann Financial Statement Overview

Summary
Financial risk remains elevated: revenue is slightly down TTM (~-2%) with weak profitability (low ~13% gross margin and ~-19% net margin) and persistent negative equity. Positives include improved operating results versus 2023 (EBIT turning positive) and a meaningful shift to positive operating/free cash flow (~$0.9M TTM), but the capital structure is still stressed.
Income Statement
26
Negative
Balance Sheet
14
Very Negative
Cash Flow
58
Neutral
BreakdownTTMSep 2025Sep 2024Sep 2023Sep 2022Jun 2021
Income Statement
Total Revenue13.72M14.25M13.80M13.59M13.53M10.32M
Gross Profit1.83M1.55M4.08M3.86M3.73M3.49M
EBITDA-1.04M-817.35K493.74K-4.68M-1.85M-2.69M
Net Income-2.64M-2.69M-1.49M-6.88M-3.96M-5.15M
Balance Sheet
Total Assets6.38M6.41M9.55M10.26M16.75M17.27M
Cash, Cash Equivalents and Short-Term Investments515.15K598.20K552.47K248.42K714.83K1.06M
Total Debt5.17M5.00M6.21M6.38M6.08M5.91M
Total Liabilities12.13M11.61M12.15M11.29M10.16M9.96M
Stockholders Equity-6.24M-5.81M-3.30M-1.72M5.86M6.49M
Cash Flow
Free Cash Flow906.77K1.12M1.49M-1.21M-2.73M-962.15K
Operating Cash Flow923.45K1.14M1.49M-452.73K-2.07M-221.16K
Investing Cash Flow1.55M1.55M52.96K-708.88K2.07M-872.05K
Financing Cash Flow-2.49M-2.51M-1.10M-134.36K720.69K1.57M

CordovaCann Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
C$4.39M-1.6650.26%-2.84%-228.77%
42
Neutral
C$4.95M-6.67-167.41%-31.51%50.00%
42
Neutral
C$2.24M-2.8757.31%19.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:CDVA
CordovaCann
0.04
-0.02
-27.27%
TSE:BBM
Blueberries Medical
0.01
>-0.01
-33.33%
TSE:BAMM
Body & Mind
0.03
0.00
0.00%
TSE:CVGR
City View Green Holdings
0.05
0.02
125.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 31, 2026